Malignant pleural mesothelioma (MPM) is diagnosed and treated at the Penn Mesothelioma and Pleural Program and the Abramson Cancer Center at Penn Medicine. In addition to advanced treatments, clinical trials are ongoing to evaluate a promising new gene therapy approach to MPM.
Related Links
- View Clinical Briefing: Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer for Malignant Pleural Mesothelioma
- View Enrolling Clinical Trial Information: A pilot and feasibility trial evaluating gene therapy for the treatment of malignant mesothelioma
- View the CME Program "Pleural Mesothelioma 2013: Multidisciplinary Diagnosis, Treatment and Investigation"
Published
Created by
BROADCASTMED